Vanillin Differentially Affects Azoxymethane-Injected Rat Colon Carcinogenesis and Gene Expression

다국어 초록 (Multilingual Abstract)

Vanillin is the substance responsible for the flavor and smell of vanilla, a widely used flavoring agent. Previous studies reported that vanillin is a good antimutagen and anticarcinogen. However, there are also some contradicting findings showing that vanillin was a comutagen and cocarcinogen. This study investigated whether vanillin is an anticarcinogen or a cocarcinogen in rats induced with azoxymethane (AOM). Rats induced with AOM will develop aberrant crypt foci (ACF). AOM-challenged rats were treated with vanillin orally and intraperitoneally at low and high concentrations and ACF density, multiplicity, and distribution were observed. The gene expression of 14 colorectal cancer-related genes was also studied. Results showed that vanillin consumed orally had no effect on ACF. However, high concentrations (300 mg/kg body weight) of vanillin administered through intraperitoneal injection could increase ACF density and ACF multiplicity. ACF were mainly found in the distal colon rather than in the mid-section and proximal colon. The expression of colorectal cancer biomarkers, protooncogenes, recombinational repair, mismatch repair, and cell cycle arrest, and tumor suppressor gene expression were also affected by vanillin. Vanillin was not cocarcinogenic when consumed orally. However, it was cocarcinogenic when being administered intraperitoneally at high concentration. Hence, the use of vanillin in food should be safe but might have cocarcinogenic potential when it is used in high concentration for therapeutic purposes.

참고문헌 (Reference)

1 Bythrow JD, "Vanilla as a medicinal plant" 3 : 129-121, 2005

2 Ho K, "Toxicology study of vanillin on rats via oral and intra-peritoneal administration" 49 : 25-30, 2011

3 Santos JH, "The synergistic effects of vanillin on recombination predominate over its antimutagenic action in relation to MMC-induced lesions in somatic cells of Drosophila melanogaster" 444 : 355-365, 1999

4 Bird RP, "The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer" 112 : 395-402, 2000

5 Sasaki YF, "Suppressing effects of vanillin, cinnamaldehyde, and anisaldehyde on chromosome aberrations induced by x-rats in mice" 243 : 299-302, 1990

6 Kunkel TA, "Slippery DNA and diseases" 365 : 207-208, 1993

7 Takagi Y, "Roles of MGMT and MLH1 proteins in alkylationinduced apoptosis and mutagenesis" 2 : 1135-1146, 2003

8 Bird RP, "Role of aberrant crypt foci in understanding the pathogenesis of colon cancer" 93 : 55-71, 1995

9 Hickman MJ, "Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents" 96 : 10764-10769, 1999

10 Olsson M, "Repair of alkylated DNA in Escherichia coli. Methyl group transfer from O6-methylguanine to a protein cysteine residue" 255 : 10569-10571, 1980

11 Hong MY, "Relationship between DNA adduct levels, repair enzyme, and apoptosis as a function of DNA methylation by azoxymethane" 10 : 749-758, 1999

12 Masir N, "RCL-2, a potential formalin substitute for tissue fixation in routine pathological specimens" 60 : 804-815, 2012

13 Bird RP, "Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings" 37 : 147-151, 1987

14 Leach FS, "Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer" 75 : 1215-1225, 1993

15 Markowits SD, "Molecular origins of cancer: Molecular basis of colorectal cancer" 361 : 2449-2460, 2009

16 Akagi K, "Modulating effects of ellagic acid, vanillin and quercetin in a rat medium term multi-organ carcinogenesis model" 94 : 113-121, 1995

17 Stojic L, "Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase" 18 : 1331-1344, 2004

18 Abraham DJ, "Method of calming or sedating an animal with a hydroxyl benzaldehyde compound. U.S. Patent 5668182"

19 Shivapurkar N, "K-ras and p53 mutations in aberrant crypt foci and colonic tumours from colon cancer patients" 115 : 39-46, 1997

20 Ohta T, "Inhibitory effects of flavorings on mutagenesis induced by chemicals in bacteria" 24 : 51-54, 1986

21 Arnaudeau C, "Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells" 461 : 221-228, 2000

22 He G, "Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities" 24 : 2929-2943, 2005

23 Cohen FO, "In vitro UV mutagenesis associated with nucleotide excision-repair gaps in Escherichia coli" 269 : 4953-4958, 1994

24 Vansant G, "Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: A case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening" 25 : 85-94, 2006

25 Ito M, "Factors controlling cyclin B expression" 43 : 677-690, 2000

26 Ghavam-Nasiri M, "Expression of p53 in colorectal carcinoma: Correlation with clinicopathologic features" 10 : 38-42, 2007

27 Bjelland S, "Excision of 3-methylguanine from alkylated DNA by 3-methyladenine DNA glycosylases I of Escherichia coli" 21 : 2045-2049, 1993

28 Hawn MT, "Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint" 55 : 3721-3725, 1995

29 Sasaki YF, "Effects of vanillin on sister-chromatid exchanges and chromosome aberrations induced by mitomycin C in cultured Chinese hamster ovary cells" 191 : 193-200, 1987

30 Xiao R, "Dietary whey protein lowers serum C-peptide concentration and duodenal SREBP-1cmRNAabundance, and reduces occurrence of duodenal tumours and colon aberrant crypt foci in azoxymethanetreated male rats" 17 : 626-634, 2006

31 Straaten FV, "Complete nucleotide sequence of a humanc-onc gene: Deduced amino acid sequence of the human c-fos protein" 80 : 3183-3187, 1983

32 Ho K, "Apoptosis and cell cycle arrest of human colorectal cancer cell line HT-29 induced by vanillin" 33 : 155-160, 2009

33 Ferguson LR, "Antimutagens as cancer chemopreventive agents in the diet" 307 : 395-410, 1994

34 Kuroda Y, "Antimutagenesis by factors affecting DNA repair in bacteria" 202 : 387-391, 1988

35 Fahrig R, "Anti-mutagenic agents are also co-recombinogenic and can be converted into co-mutagens" 350 : 59-67, 1996